-
BeiGene's Q1 2025 Financial report
Market Trend
BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
-
-
-
Pfizer's Q1 2025 Financial report
Market Trend
Pfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
-
Eli Lilly's Q1 2025 Financial report
Market Trend
Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
-
-
Novartis's Q1 2025 Financial report
Market Trend
Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
-
-
WuXi AppTec's Q1 2025 Financial report
Market Trend
WuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
-
深水埗区|
昭平县|
辽阳县|
任丘市|
宕昌县|
五大连池市|
北安市|
定安县|
永平县|
江都市|
永安市|
进贤县|
长寿区|
古浪县|
枣强县|
双鸭山市|
溆浦县|
昌宁县|
嘉义市|
垣曲县|
芜湖县|
文安县|
盱眙县|
和静县|
临漳县|
密云县|
察雅县|
天等县|
宜章县|
平果县|
龙口市|
平阳县|
中阳县|
哈密市|
百色市|
秭归县|
五台县|
达孜县|
舒城县|
曲水县|
英德市|